Tralokinumab: Discovering the Promise of LP 0162 and CAT-354 Tralokinumab, previously known as LP 0162 and CAT-354, represents a promising approach for chronic dermatitis. This monoclonal antibody targets IL-13, a key mediator involved in the pathogenesis of the disease . Clinical s

Elotuzumab, a novel innovative unique antibody, demonstrates exhibits presents its therapeutic clinical beneficial effect by selectively specifically primarily targeting Siglec-8, an the a membrane surface cell glycoprotein overexpressed present found on certain specific some multiple myeloma cel

Gemtuzumab Ozogamicin represents a novel breakthrough in the treatment of severe leukemic malignancy, specifically aggressive blood malignancy (AML). This antibody-drug joins a monoclonal immunoglobulin specific against the receptor marker located on leukemic populations with a cytotoxic payload,